| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/26/2001 | WO2001053461A1 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 07/26/2001 | WO2001053353A2 Recombinant antibodies to human interkleukin-1 beta |
| 07/26/2001 | WO2001053348A2 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053288A1 Novel piperidine compounds and drugs containing the same |
| 07/26/2001 | WO2001053284A1 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram |
| 07/26/2001 | WO2001053279A1 Urea compounds as inhibitors for vla-4 |
| 07/26/2001 | WO2001053263A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | WO2001053261A1 Substituted glutarimides and use thereof il-12 production inhibitors |
| 07/26/2001 | WO2001053257A2 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 07/26/2001 | WO2001053256A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same |
| 07/26/2001 | WO2001053255A1 Gamma-secretase inhibitors |
| 07/26/2001 | WO2001052903A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | WO2001052902A1 Antisense modulation of inducible nitric oxide synthase expression |
| 07/26/2001 | WO2001052885A1 Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| 07/26/2001 | WO2001052878A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 07/26/2001 | WO2001052876A1 Ophthalmic compositions for treating ocular hypertension |
| 07/26/2001 | WO2001052865A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | WO2001052862A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | WO2001052857A1 Drospirenone for hormone replacement therapy |
| 07/26/2001 | WO2001052855A2 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| 07/26/2001 | WO2001052854A1 Nk1-receptor antagonists for treatment of restless legs syndrome |
| 07/26/2001 | WO2001052853A1 Anxiety method |
| 07/26/2001 | WO2001052851A1 Methods for the treatment of substance abuse |
| 07/26/2001 | WO2001052847A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 07/26/2001 | WO2001052845A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | WO2001052844A1 Brain, spinal and nerve injury treatment |
| 07/26/2001 | WO2001052841A1 Decursinol or derivative thereof as analgesic agent |
| 07/26/2001 | WO2001052815A1 Multi-step drug dosage forms |
| 07/26/2001 | WO2001052664A1 Immune modulation with death receptor-induced apoptosis |
| 07/26/2001 | WO2001022944A8 Oral controlled release formulations |
| 07/26/2001 | WO2001014415A3 Egfh2 genes and gene products |
| 07/26/2001 | WO2001001748A3 Peptide compounds that bind her2 |
| 07/26/2001 | WO2000071741A9 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 07/26/2001 | WO2000068183A3 High purity (1r,2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them |
| 07/26/2001 | WO2000047238A9 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients |
| 07/26/2001 | WO2000041566A9 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/26/2001 | WO2000017361A3 Interferon-epsilon |
| 07/26/2001 | US20010009924 Methods of providing symptomatic and prophylactic neuroprotection |
| 07/26/2001 | US20010009921 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 07/26/2001 | US20010009915 Nitrogen oxide yielding and thromboxane A2 (TXA2) and serotonin (5HT2) receptor antagonist; treatment of atherothrombotic cardiovascular disorders |
| 07/26/2001 | US20010009899 Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects |
| 07/26/2001 | DE10002509A1 New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
| 07/26/2001 | DE10000577A1 Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
| 07/26/2001 | CA2406732A1 Anxiety method |
| 07/26/2001 | CA2398388A1 Novel piperidine compound and pharmaceutical thereof |
| 07/26/2001 | CA2398343A1 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | CA2398239A1 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 07/26/2001 | CA2398061A1 Substituted glutarimides and their use as inhibitors of il-12 production |
| 07/26/2001 | CA2397946A1 Lipid metabolism enzymes |
| 07/26/2001 | CA2397783A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | CA2397726A1 Methods for the treatment of substance abuse |
| 07/26/2001 | CA2397686A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397627A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 07/26/2001 | CA2397617A1 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 07/26/2001 | CA2397543A1 Gamma-secretase inhibitors |
| 07/26/2001 | CA2397531A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same |
| 07/26/2001 | CA2397508A1 Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| 07/26/2001 | CA2397492A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | CA2397324A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom |
| 07/26/2001 | CA2397205A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | CA2397202A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | CA2396979A1 Immune modulation with death receptor-induced apoptosis |
| 07/26/2001 | CA2396935A1 Phosphatases |
| 07/26/2001 | CA2396697A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | CA2396319A1 Ophthalmic compositions for treating ocular hypertension |
| 07/26/2001 | CA2396212A1 Recombinant antibodies to human interleukin-1 beta |
| 07/26/2001 | CA2396066A1 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| 07/26/2001 | CA2395974A1 Multi-step drug dosage forms |
| 07/26/2001 | CA2395054A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | CA2332208A1 Pharmacophore models for, methods of screening for, and identification of the cytochrome p-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 07/25/2001 | EP1118663A1 Nucleic acids encoding chemotaxis inhibitory polypeptides |
| 07/25/2001 | EP1118614A2 Process for the preparation of 5-carboxyphthalide |
| 07/25/2001 | EP1118612A1 Piperazine derivatives possesing nootropic activity |
| 07/25/2001 | EP1118610A1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 07/25/2001 | EP1118324A1 Analgesic agent comprising a cyclobutanedicarboxylic acid derivative |
| 07/25/2001 | EP1117840A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 07/25/2001 | EP1117801A2 Polyketide synthase enzymes and recombinant dna constructs therefor |
| 07/25/2001 | EP1117796A2 Calcium channel alpha-2/delta gene |
| 07/25/2001 | EP1117785A1 Human kinesin-like motor protein |
| 07/25/2001 | EP1117781A2 Human membrane channel proteins |
| 07/25/2001 | EP1117776A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 07/25/2001 | EP1117764A1 Primate embryonic stem cells with compatible histocompatibility genes |
| 07/25/2001 | EP1117695A1 Biocompatible polymers, preparation method and compositions containing same |
| 07/25/2001 | EP1117682A1 Novel peptides |
| 07/25/2001 | EP1117681A1 Novel peptides |
| 07/25/2001 | EP1117680A2 Ncam binding compounds |
| 07/25/2001 | EP1117675A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 07/25/2001 | EP1117667A1 BENZOTHIENO[3,2-c]PYRIDINES AS ALPHA2 ANTAGONISTS |
| 07/25/2001 | EP1117663A2 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| 07/25/2001 | EP1117662A1 Benzimidazolinyl piperidines as cgrp ligands |
| 07/25/2001 | EP1117658A1 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders |
| 07/25/2001 | EP1117657A1 Phenylalanine derivatives as alpha 4 integrin inhibitors |
| 07/25/2001 | EP1117648A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 07/25/2001 | EP1117640A1 Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals |
| 07/25/2001 | EP1117628A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 07/25/2001 | EP1117429A1 Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
| 07/25/2001 | EP1117425A2 Methods for the treatment of non-thyroid disorders |